162 related articles for article (PubMed ID: 21690477)
1. Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center.
Cleeland CS; Mendoza TR; Wang XS; Woodruff JF; Palos GR; Richman SP; Nazario A; Lynch GR; Liao KP; Mobley GM; Lu C
J Clin Oncol; 2011 Jul; 29(21):2859-65. PubMed ID: 21690477
[TBL] [Abstract][Full Text] [Related]
2. Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer.
Palos GR; Mendoza TR; Liao KP; Anderson KO; Garcia-Gonzalez A; Hahn K; Nazario A; Ramondetta LM; Valero V; Lynch GR; Jibaja-Weiss ML; Cleeland CS
Cancer; 2011 Mar; 117(5):1070-9. PubMed ID: 20960510
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
4. Socioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference.
Fagundes C; Jones D; Vichaya E; Lu C; Cleeland CS
J Thorac Oncol; 2014 Oct; 9(10):1459-63. PubMed ID: 25170640
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms.
Wang XS; Fairclough DL; Liao Z; Komaki R; Chang JY; Mobley GM; Cleeland CS
J Clin Oncol; 2006 Sep; 24(27):4485-91. PubMed ID: 16983118
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy.
Wang XS; Shi Q; Williams LA; Mao L; Cleeland CS; Komaki RR; Mobley GM; Liao Z
Brain Behav Immun; 2010 Aug; 24(6):968-74. PubMed ID: 20353817
[TBL] [Abstract][Full Text] [Related]
7. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
[TBL] [Abstract][Full Text] [Related]
9. Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
Shallwani SM; Simmonds MJ; Kasymjanova G; Spahija J
Lung Cancer; 2016 Sep; 99():69-75. PubMed ID: 27565917
[TBL] [Abstract][Full Text] [Related]
10. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
[TBL] [Abstract][Full Text] [Related]
11. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
[TBL] [Abstract][Full Text] [Related]
12. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
13. Symptom clusters and quality of life in China patients with lung cancer undergoing chemotherapy.
Wang D; Fu J
Afr Health Sci; 2014 Mar; 14(1):49-55. PubMed ID: 26060457
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.
Davidoff AJ; Tang M; Seal B; Edelman MJ
J Clin Oncol; 2010 May; 28(13):2191-7. PubMed ID: 20351329
[TBL] [Abstract][Full Text] [Related]
16. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study.
Iyer S; Roughley A; Rider A; Taylor-Stokes G
Support Care Cancer; 2014 Jan; 22(1):181-7. PubMed ID: 24026981
[TBL] [Abstract][Full Text] [Related]
17. Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy.
Wong ML; Paul SM; Cooper BA; Dunn LB; Hammer MJ; Conley YP; Wright F; Levine JD; Walter LC; Cartwright F; Miaskowski C
Support Care Cancer; 2017 Jun; 25(6):1931-1939. PubMed ID: 28160076
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of weekly symptom telemonitoring in advanced lung cancer.
Yount SE; Rothrock N; Bass M; Beaumont JL; Pach D; Lad T; Patel J; Corona M; Weiland R; Del Ciello K; Cella D
J Pain Symptom Manage; 2014 Jun; 47(6):973-89. PubMed ID: 24210705
[TBL] [Abstract][Full Text] [Related]
19. What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer.
LeBlanc TW; Nickolich M; Rushing CN; Samsa GP; Locke SC; Abernethy AP
Support Care Cancer; 2015 Dec; 23(12):3455-63. PubMed ID: 25791391
[TBL] [Abstract][Full Text] [Related]
20. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
